Only 1 in 5 Suspected FH Patients Have a Detectable Gene Mutation
A comprehensive review reveals the complex genetic architecture of familial hypercholesterolaemia, where polygenic and Lp(a) mechanisms explain most 'mutation-negative' cases.
Summary
Familial hypercholesterolaemia (FH) is one of the most common inherited disorders, affecting roughly 1 in 280 people and dramatically raising heart disease risk through elevated LDL cholesterol. This review from UCL reveals that genetic testing detects a causative mutation in only about 21% of clinically diagnosed FH patients. The remaining majority are explained not by a single gene defect, but by an accumulation of many common variants — a polygenic pattern — or by overproduction of Lp(a), a distinct lipoprotein particle. Four genes (LDLR, APOB, PCSK9, APOE) account for all known monogenic FH, with LDLR variants being by far the most common. Understanding this genetic complexity has major implications for how FH is diagnosed, how relatives are screened, and how aggressively patients are treated with statins and newer lipid-lowering therapies.
Detailed Summary
Familial hypercholesterolaemia (FH) has been recognized as a hereditary disorder for over 85 years, first described by Norwegian physician Carl Müller in 1939. It is characterized by lifelong elevation of LDL cholesterol from birth, and without treatment, men with FH face a 50% risk of fatal or non-fatal coronary heart disease (CHD) by age 50, while women face a 30% risk by age 60. The condition is classified clinically using tools like the Simon Broome criteria and Dutch Lipid Clinic Network (DLCN) scoring, which weigh LDL-C levels, family history, and physical stigmata such as tendon xanthomas. Both tools require ruling out secondary causes of elevated LDL-C before a diagnosis is confirmed.
Monogenic FH is caused by pathogenic variants in four genes: LDLR, APOB, PCSK9, and APOE — all encoding proteins central to hepatic LDL clearance. The LDLR gene, spanning 45 kilobases on chromosome 19 with 18 exons, is by far the most commonly implicated, with over 2,300 variants identified. A 2018 ClinVar analysis classified 2,314 LDLR variants: 70% were predicted pathogenic, while only 8% remained variants of uncertain significance (VUS). Pathogenic APOB variants, particularly the p.(Arg3527Gln) substitution found in ~1 in 2,000 Europeans, cause a milder FH phenotype. Gain-of-function PCSK9 variants and gain-of-function APOE variants (notably p.Leu167del) round out the monogenic causes, though all are far less common than LDLR mutations.
Despite the scientific clarity around these four genes, the real-world detection rate remains strikingly low. In the UK between 2022 and 2023, 23,855 index cases were genetically tested and only 5,126 (21.6%) carried an identifiable FH-causing variant. This gap has been substantially explained by polygenic mechanisms. Studies using a genetic risk score (GRS) composed of multiple common LDL-raising SNPs have shown that 'no-variant' FH patients tend to inherit a greater-than-average number of these small-effect alleles. A 12-SNP GRS demonstrated that individuals in the top quintile of polygenic burden had LDL-C elevations comparable to monogenic FH carriers, leading to the proposed term 'polygenic hypercholesterolaemia' for this group.
A further important contributor to the 'mutation-negative' FH phenotype is elevated Lp(a), a structurally LDL-like particle encoded by the LPA gene. Lp(a) is measured by immunoassay and can substantially inflate apparent LDL-C when standard Friedewald calculations are used, as most assays cannot distinguish Lp(a) cholesterol from LDL-C. Studies using corrected LDL-C estimates have shown that a meaningful fraction of clinically diagnosed FH patients who lack monogenic variants actually have high Lp(a) as the primary driver of their phenotype. Lp(a) levels are predominantly determined by the number of kringle IV type 2 (KIV-2) repeats in the LPA gene — a highly heritable, inversely correlated locus.
The clinical stakes are high because the distinction between monogenic, polygenic, and Lp(a)-driven FH has direct treatment and screening implications. Monogenic variant carriers have the highest cardiovascular risk and warrant the most aggressive LDL-lowering therapy; they also benefit from cascade genetic testing of relatives, which can identify at-risk family members with high efficiency and at low cost. Polygenic cases, by contrast, carry a more moderate CHD risk and their relatives are less likely to be affected. Lp(a)-driven cases may specifically benefit from emerging Lp(a)-lowering therapies rather than intensified statin treatment alone. The authors call for further research into additional FH-causing genes and improved polygenic risk score methodologies across diverse ancestral populations.
Key Findings
- Only 21.6% of 23,855 UK clinical FH index cases tested between 2022–2023 carried an identifiable pathogenic variant in LDLR, APOB, PCSK9, or APOE.
- LDLR harbors over 2,300 reported variants; a 2018 ClinVar analysis classified 70% as pathogenic/likely pathogenic, with only 8% remaining as variants of uncertain significance (VUS).
- The APOB p.(Arg3527Gln) variant, the most common single FH-causing variant in non-Finnish Europeans, has a population frequency of ~0.00049 (approximately 1 in 2,000) per gnomAD v4.1.0.
- Without treatment, men with FH have a 50% risk of fatal or non-fatal CHD by age 50; women have a 30% risk by age 60.
- HeFH affects approximately 1 in 250–300 individuals in the general population; HoFH, far more severe, occurs in roughly 3 per million.
- Polygenic hypercholesterolaemia — driven by accumulation of common small-effect LDL-raising SNPs — explains the majority of 'mutation-negative' clinical FH cases, with a 12-SNP GRS distinguishing monogenic from polygenic individuals.
- Elevated Lp(a), largely determined by KIV-2 repeat number in the LPA gene, can mimic the FH phenotype and represents a distinct, underrecognized cause of 'mutation-negative' clinical FH.
Methodology
This is a comprehensive narrative review article (not a primary research study), drawing on decades of published molecular genetics, population genetics, clinical cohort data, and bioinformatics analyses. Key data sources include the UK Simon Broome FH Register, the ClinVar FH variant database (Iacocca et al. 2018), gnomAD v4.1.0 population frequency data, and published GWAS and polygenic risk score studies. The review covers UK national genetic testing data from 2022 to 2023 (n = 23,855 index cases) to contextualize real-world variant detection rates. No formal meta-analytic statistical methods are applied; findings are synthesized qualitatively across the cited literature.
Study Limitations
As a narrative review, the paper does not employ systematic search methods or formal evidence grading, limiting its objectivity in synthesizing the literature. The review focuses predominantly on European populations; polygenic risk scores and variant detection rates may not generalize well to non-European ancestries, a limitation the authors acknowledge. The authors declare funding from the British Heart Foundation and NIHR, with no explicit conflicts of interest reported, though both authors have long-standing institutional involvement in FH research and related diagnostic programs.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.